Venus Remedies advanced 2.29% to Rs 383.35 after the company announced it has been awarded a tender by the VVHO-backed Pan American Health Organisation for supplying essential cancer drugs to multiple Latin American countries.

Venus Remedies edges higher after bagging supply order for oncology drugs from PAHO

The uptick in stock price came after the company announced that it has secured an award for its antibiotic product, Ceftriaxone 1 gm, from UNICEF

Venus Remedies up 8% on order win from UNICEF for bacterial infection drug

Venus Remedies jumped 5.34% to Rs 374.10 after the company announced that it has secured a contract for supplying its antibiotic product Ceftriaxone from UNICEF in the Beta Lactam tender.

Venus Remedies soars after bagging Ceftriaxone supply contract from UNICEF

The approved drugs include bortezomib, cisplatin, doxorubicin, docetaxel, fluorouracil, and paclitaxel, which are crucial for cancer treatment, according to a company statement.

Venus Remedies gets marketing approval for six chemotherapy drugs from Philippines

“The company has secured marketing authorisation from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs beneficial in the treatment of various types of cancer,” the company said in a regulatory filing.

Venus Remedies trades 2% up on approval to market cancer drugs in Serbia

Venus Remedies has launched its R&D drug Elores, which is effective against multiple drug-resistant Gram-negative bacteria and has been patented in 46 countries including Japan and the US, in Oman’s $7.5m antimicrobial market. Elores is aiming to capture 0.5% of the segment by 2025.

Venus Remedies launches flagship R&D drug Elores in Oman

With this, the company has secured 506 marketing approvals for its oncology products across 76 countries.

Venus Remedies gets market authorisations for cancer drugs from Philippines, Praguay, Georgia, Moldova

SEBI recently introduced ESM framework for micro and small companies with market cap below 500 crore, leading to trading restrictions based on price variations.

Venus Remedies stops trading as sharp rally triggers enhanced surveillance measures by Sebi

The company has secured 503 marketing approvals for its oncology products across 75 countries.

Venus Remedies jumps 3% on nod to operate in 4 foreign markets

With this, it has secured 503 marketing approvals for its oncology products across 75 countries, a company statement said.

Venus Remedies gets marketing approval from different countries for chemotherapy drugs

Will be able to capture a 10% share in the $6.34-million meropenem market of Spain

Venus Remedies gets nod to sell generic antibiotic in Spain

Price return has been average, nothing exciting

Performance

Can be considered moderately valued vs the market

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Venus Remedies Limited is engaged in pharmaceutical product manufacturing business. The Company provides formulations and manufactures dosage injectables.